3-(7-Oxabicyclo[2.2.1]heptan-2-yl)thiazepane 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫氮卓类
• 英文名称: 3-(7-Oxabicyclo[2.2.1]heptan-2-yl)thiazepane 1,1-dioxide
• 英文别名: 3-(7-oxabicyclo[2.2.1]heptan-2-yl)thiazepane 1,1-dioxide
• 化学式: C₁₁H₁₉NO₃S
• 分子量: 245.34
• InChiKey: RPCARHKBQCCZAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Histone deacetylase inhibitors and methods for use thereof
  申请人：Reaction Biology Corp.

  公开号：US10011611B2

  公开（公告）日：2018-07-03

  The present invention relates to methods of modulating (for example inhibiting) activity of histone deacetylases (HDACs) and/or treating HDACs-associated diseases including, for example, cancers, inflammatory disorders, neurodegenerative disorders, etc. The invention also provides novel compounds and compositions thereof, methods of preparation of the same, as well as methods of use of the same for inhibition of HDACs and/or treatment of HDAC-associated diseases.

  本发明涉及调节（例如抑制）组蛋白去乙酰化酶（HDACs）活性和/或治疗HDACs相关疾病（包括癌症、炎症性疾病、神经退行性疾病等）的方法。本发明还提供了用于抑制 HDAC 和/或治疗 HDAC 相关疾病的新型化合物及其组合物、制备方法以及使用方法。
• Fused bicyclic compounds for the treatment of disease
  申请人：AKARNA THERAPEUTICS, LTD.

  公开号：US10167294B2

  公开（公告）日：2019-01-01

  Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

  本文描述了融合双环化合物、组合物及其用于治疗疾病的方法。
• Hepatitis B antiviral agents
  申请人：Novira Therapeutics, Inc.

  公开号：US10196376B2

  公开（公告）日：2019-02-05

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种在有需要的个体中抑制、抑制或预防 HBV 感染的方法，包括向该个体施用治疗有效量的至少一种本发明化合物。
• Phosphonate-chloroquine conjugates and methods using same
  申请人：University of Rochester

  公开号：US10660884B2

  公开（公告）日：2020-05-26

  The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

  本发明提供了用于提供氯喹（CQ）和双磷酸盐共轭物的可控局部给药的组合物和方法，以治疗以骨代谢异常为特征的疾病。在某些实施方案中，本发明可用于治疗以骨质流失为特征的疾病和失调。
• LPA RECEPTOR MODULATORS FOR BROWN FAT DIFFERENTIATION
  申请人：The California Institute for Biomedical Research

  公开号：US20170042915A1

  公开（公告）日：2017-02-16

  Described herein is a method of increasing brown fat differentiation or increasing energy expenditure in a subject in need thereof, the method comprising administering to the subject an LPA receptor modulator, or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, deuteride, N-oxide, stereoisomer, or isomer thereof.